MORC3 and dermatomyositis: Clinical features of dermatomyositis in the presence of anti-NXP2 antibodies can include the development of characteristic cutaneous manifestations, calcinosis cutis (which is prevalent in up to 37% of patients) as well as an increased prevalence of peripheral edema (58).